Robust results
-- Robust quarter despite meaningful impact from Omicron variant
-- Record results in Q2 FY’22 for SOZO®SaaS revenue
-- $50.8m cash balance and fully funded to cashflow break-even post capital raising
PREVENT Trial
-- PREVENT Trial peer-reviewed, accepted and pending publication in coming days
-- Met primary end point
-- Statistically significant
-- Showed statistical benefit across all risk factors
Foundation laid for accelerated growth
-- Rapidly expanding our Case Assistance Program (CAP) due to its overwhelming success
-- CAP will be strengthened by PREVENT Trial publication
-- Principal Investigators to submit NCCNapplication in the coming week
-- Measured expansion of customer facing resources as we accelerate growth
For more information, download the attached PDF.
Download this document
